Compile Data Set for Download or QSAR
Report error Found 1498 of affinity data for UniProtKB/TrEMBL: P04628
TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 562108BDBM562108(US11401260, Compound 1 | 7-(3-[4,4-bis(hydroxymeth...)
Affinity DataKd:  0.380nMAssay Description:A competition binding assay, was used to measure the ability of a compound to compete for binding of an immobilized adenosine triphosphate (ATP) site...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384029BDBM384029(US10280166, Compound 346)
Affinity DataIC50: 0.400nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384033BDBM384033(US10280166, Compound 372)
Affinity DataIC50: 0.600nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383939BDBM383939(US10280166, Compound 7)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383959BDBM383959(US10280166, Compound 25)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383956BDBM383956(US10280166, Compound 19)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384010BDBM384010(US10280166, Compound 277)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383918BDBM383918(US10280166, Compound 1)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383965BDBM383965(US10280166, Compound 55)
Affinity DataIC50: 1.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384020BDBM384020(US10280166, Compound 313)
Affinity DataIC50: 2nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383937BDBM383937(US10280166, Compound 2)
Affinity DataIC50: 2nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383963BDBM383963(US10280166, Compound 46)
Affinity DataIC50: 2nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383991BDBM383991(US10280166, Compound 184)
Affinity DataIC50: 2.30nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383946BDBM383946(US10280166, Compound 9)
Affinity DataIC50: 3nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 445829BDBM445829(US10669240, Compound 1141)
Affinity DataIC50: 3nMAssay Description:Reporter cell lines were generated by stably transducing cells of cancer cell lines (e.g., colon cancer) with a lentiviral construct that include a W...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384039BDBM384039(US10280166, Compound 433)
Affinity DataIC50: 3nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383972BDBM383972(US10280166, Compound 82)
Affinity DataIC50: 3.5nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 346341BDBM346341(US10202377, Compound 367)
Affinity DataIC50: 3.5nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383960BDBM383960(US10280166, Compound 28)
Affinity DataIC50: 4nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 445759BDBM445759(US10669240, Compound 55)
Affinity DataIC50: 4nMAssay Description:Reporter cell lines were generated by stably transducing cells of cancer cell lines (e.g., colon cancer) with a lentiviral construct that include a W...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 346315BDBM346315(US10202377, Compound 269)
Affinity DataIC50: 4.20nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384032BDBM384032(US10280166, Compound 367)
Affinity DataIC50: 4.30nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 346283BDBM346283(US10202377, Compound 82)
Affinity DataIC50: 4.5nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383993BDBM383993(US10280166, Compound 202)
Affinity DataIC50: 4.70nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384028BDBM384028(US10280166, Compound 340)
Affinity DataIC50: 4.90nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384057BDBM384057(US10280166, Compound 1875)
Affinity DataIC50: 5nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 445758BDBM445758(US10669240, Compound 54)
Affinity DataIC50: 5nMAssay Description:Reporter cell lines were generated by stably transducing cells of cancer cell lines (e.g., colon cancer) with a lentiviral construct that include a W...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384016BDBM384016(US10280166, Compound 298)
Affinity DataIC50: 5nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384007BDBM384007(US10280166, Compound 269)
Affinity DataIC50: 5.10nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384015BDBM384015(US10280166, Compound 295)
Affinity DataIC50: 5.10nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384011BDBM384011(US10280166, Compound 279)
Affinity DataIC50: 5.20nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383971BDBM383971(US10280166, Compound 81)
Affinity DataIC50: 5.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384041BDBM384041(US10280166, Compound 442)
Affinity DataIC50: 5.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384017BDBM384017(US10280166, Compound 304)
Affinity DataIC50: 6nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383967BDBM383967(US10280166, Compound 61)
Affinity DataIC50: 6nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384037BDBM384037(US10280166, Compound 421)
Affinity DataIC50: 6.10nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 346318BDBM346318(US10202377, Compound 280)
Affinity DataIC50: 6.20nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384026BDBM384026(US10280166, Compound 333)
Affinity DataIC50: 6.30nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384034BDBM384034(US10280166, Compound 373)
Affinity DataIC50: 6.40nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384006BDBM384006(US10280166, Compound 268)
Affinity DataIC50: 6.5nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384018BDBM384018(US10280166, Compound 306)
Affinity DataIC50: 6.70nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 346320BDBM346320(US10202377, Compound 288)
Affinity DataIC50: 6.80nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383973BDBM383973(US10280166, Compound 87)
Affinity DataIC50: 6.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384031BDBM384031(US10280166, Compound 358)
Affinity DataIC50: 6.90nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 445786BDBM445786(US10669240, Compound 82)
Affinity DataIC50: 7nMAssay Description:Reporter cell lines were generated by stably transducing cells of cancer cell lines (e.g., colon cancer) with a lentiviral construct that include a W...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383992BDBM383992(US10280166, Compound 190)
Affinity DataIC50: 7.40nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 346309BDBM346309(US10202377, Compound 238)
Affinity DataIC50: 7.70nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 383983BDBM383983(US10280166, Compound 148)
Affinity DataIC50: 8.10nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384009BDBM384009(US10280166, Compound 271)
Affinity DataIC50: 8.40nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 384022BDBM384022(US10280166, Compound 320)
Affinity DataIC50: 8.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

Displayed 1 to 50 (of 1498 total ) | Next | Last >>
Jump to: